China At Global Rare Disease Crossroads: CANbridge CEO
Reimbursement, Regulatory Changes Herald New Era?
The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.
